SecBot SecBot

PYXS

Pyxis Oncology, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001782223 Biotech & Drug Discovery
$1.41 −0.17 (−10.76%)
Nov 16 4:00 PM ET · prev $1.58
Market cap
$189.0M
Micro cap
Consensus
Buy
88% Buy or better · 16 analysts
Median target
$7.00
+396% · range $5.00–19.00
1 year
−69.7%
from $4.65 · Nov 17
30 days
−19.9%
from $1.76
52-week range
$1.06–5.34
−74% from high · low Dec 29
Avg volume 20D
762.9K
shares / day
Short interest
4.53M
≈3.8% of shares · +4.1%
Days to cover
5.8
at average volume
Insider net
−$107.1K
1 buyer · 1 seller · 12 mo
New fund stakes
1
Q3 2026 13F · 0 exits
Filing reports
19
analyzed by SecBot
SecBot read BEARISH 16 reports · 90 days
Balance 7 bearish · 1 bullish · 8 neutral oldest → newest, height = score
Avg score ·High conf. 11/16

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $107.1K.

  • InstitutionsMIXED

    Q3 2026: 12 added (1 new), 9 trimmed or exited.

  • AnalystsBULLISH

    14 of 16 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.278 → −$0.210 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +4.1% to 4.53M shares. 5.8 days to cover, ≈3.8% of shares.

  • TrendDOWNTREND

    38% below its 50-day average.

Who's buying

13F· Q3 2026
1
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCADD3,999,762$9.3M
VANGUARD FIDUCIARY TRUST COADD403,076$939.2K
RENAISSANCE TECHNOLOGIES LLCTRIM367,780$856.9K
STATE STREET CORPADD328,337$765.0K
MACKENZIE FINANCIAL CORPDOUBLED90,747$211.4K
BARCLAYS PLCDOUBLED42,293$98.5K
JANE STREET GROUP, LLCNEAR_EXIT32,667$76.1K
LPL Financial LLCTRIM32,206$75.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 88% rate it Buy or better
Strong Buy7Buy7Hold2Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +396%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 6, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Nov 6, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Sep 10, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Sep 10, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Sep 9, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Sep 9, 2026RBC Capital
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 1 insider
$107.1K
sold · 1 insider
DateInsiderTypeValue
Nov 6, 2026
HUMPHREY RACHEL
Director
Nov 6, 2026
AWARD34,500 sh
Oct 1, 2026
GordonMD Global Investments LP
10%+ Owner
Oct 1, 2026
BUY7,172,000 sh
Oct 1, 2026
GordonMD Global Investments LP
10%+ Owner
Oct 1, 2026
BUY5,517,000 sh
Oct 1, 2026
GordonMD Global Investments LP
10%+ Owner
Oct 1, 2026
BUY7,546,766 sh
Sep 4, 2026
Civik Thomas
CEO & Chairman of the Board
Sep 4, 2026
AWARD2,503,050 sh
Aug 20, 2026
Dupont Jakob
Director
Aug 20, 2026
AWARD46,000 sh
Aug 12, 2026
Civik Thomas
Interim CEO
Aug 12, 2026
AWARD250,956 sh
Jun 30, 2026
Dupont Jakob
Director
Jun 30, 2026
SELL$107.1K

Earnings setup

Estimates
−$0.21
EPS estimate, this quarter
+24%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.21-$0.31–-$0.15+18.5%$19.4K
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
4,525,205
shares short
+4.1%
vs prior settlement
5.8
days to cover
≈3.8%
of shares outstanding
Trading halts
Aug 11, 2026Volatility PauseResumed
Aug 11, 2026Volatility PauseResumed
Aug 11, 2026Volatility PauseResumed
Aug 11, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 17, 2026 Earnings calendar
🔒 Fresh data, subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 6, 2026 Insider
HUMPHREY RACHEL was granted 34,500 shares
Director
Oct 27, 2026 Press
Pyxis Oncology announced a late-breaking oral presentation of Phase 1 data for its lead ADC, micvotabart pelidotin…
Impact 4/10
Oct 2, 2026 Press
Pyxis Oncology closed a ~$110M public offering on October 1, 2026, selling 36M shares and pre-funded warrants for 1.9M…
Impact 7/10
Oct 1, 2026 Insider
GordonMD Global Investments LP bought 7,172,000 shares
10%+ Owner
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

19 filings · 6 press releases · 1 bullish · 5 bearish · 2 mixed · 11 neutral
All PYXS filing & press-release reports (25)